To explore what potential effectiveness challenges may be relevant to a particular medicine, it may be helpful to examine previous health technology assessment (HTA) reports from different countries for similar medicines and/or for other medicines on similar conditions.
It is also useful to consider how the generation of real-world evidence may change reimbursement decisions. The following reviews from two HTA agencies examined whether reimbursement decisions by the respective agency changed, following the generation of real-world evidence.
- Zorginstitut Netherlands (ZIN), the national HTA agency in the Netherlands – see Implementation of Conditional Reimbursements Schemes: Experience from the Netherlands
- Haute Autorité de Santé (HAS), the national HTA agency in France – see Comparison of Reimbursement Decisions Before and After Real-World Evidence Review in France